nmu

N-Nitroso-N-methylurea（NMU/MNU/NMH）是一种具有烷基化、致癌和致突变特性的亚硝基脲化合物，作为一种直接作用的烷基化剂可与DNA相互作用，靶向多种动物器官引发多种癌症和变性疾病，可用于诱导小鼠的胃癌以及乳腺癌等疾病模型。

NMU-25 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T64545。

Hainanmurpanin是一种天然产物，属于芸香科九里香属，其产品编号为 TN4180，CAS号为 95360-22-8。Hainanmurpanin可用作对照参考。

Pifithrin-μ (NSC-303580) 是 p53和 HSP70的抑制剂，具有抗肿瘤和神经保护作用。

Nicotinamide是一种维生素B3的衍生物，是 SIRT1 (IC50=50-180 μM) 和 SIRT2 (IC50=2 μM) 的抑制剂。Nicotinamide 可作为烟酰胺腺嘌呤二核苷酸或 NAD+ 的前体，可通过膳食摄入来补充，能预防或治疗黑舌病和糙皮病。

CPX-351 (Vyxeos) 是阿糖胞苷和柔红霉素的脂质体封装物，具有潜在的抗肿瘤活性，可用与研究急性髓系白血病。

Neuromedin S (human) 是包含33个氨基酸的神经肽，作为G 蛋白偶联受体 (GPCR) FM-4/TGR-1的内源性配体，在大脑中被鉴定，并对神经调节素 U (NMU) 受体 2 (NMUR2)调节体重稳态具有调控作用。

Blebbistatin ((±)-Blebbistatin) 是一种非肌肉肌球蛋白 II(NMII)选择性和非肌肉肌球蛋白重链9（MYH9）特异性的抑制剂，可促进角膜内皮细胞 (CEC) 的定向迁移并加速伤口愈合，并保留了细胞连接的完整性和屏障功能。

Arctigenin mustard is a tumor-growth inhibiting substance.

GSK467 是一种有效的、选择性的 KDM5 (JARID1) 抑制剂，Ki 值为10 nM。

(-)-Blebbistatin ((S)-(-)-Blebbistatin) 是 blebbistatin 的 S 对映异构体。(-)-Blebbistatin 是一种肌球蛋白 II 抑制剂 (IC50=0.5-5 μM)，具有有效性和选择性。(-)-Blebbistatin 可以用于抑制心肌肌球蛋白、非肌肉肌球蛋白II和骨骼肌肌球蛋白。

R-PSOP is a potent and selective nonpeptidic NMUR2 antagonist, exhibiting binding affinity to human and rat NMUR2 with Ki values of 52 nM and 32 nM, respectively. This compound demonstrates moderate central nervous system (CNS) penetration and is valuable in the study of eating disorders, obesity, pain, and stress-related disorders [1].

3'-Methoxyflavonol 是一种神经介肽 U 2 受体的选择性激动剂。

Neuromedin U,a 23-amino acid brain-gut peptide, regulates several important physiological functions through its cognate receptor NMUR2 in the central nervous system, including energy balance, stress response, and nociception.

CPN-351 TFA (compound 9a) 是一种具有选择性的人NMUR1拮抗作用的五肽，其pA2值为7.35。相比于NMUR2，CPN-351 TFA 对人 NMUR1 的拮抗效力高出10倍。该化合物可应用于炎症研究中。

CPN-351 (compound 9a) 是一种五肽，为人NMUR1的选择性拮抗剂，pA2值为7.35。CPN-351 对于人NMUR1的拮抗效力相较于NMUR2高出10倍。该化合物适用于炎症领域的研究。

Neuromedin U (rat) acetate 是一种 23 个氨基酸的脑肠肽。 Neuromedin U (NMU) 通过其在中枢神经系统中的同源受体 NMUR2 调节几种重要的生理功能，包括能量平衡、压力反应和伤害感受。

Neuromedin U-23 (NMU-23) is a neuropeptide involved in diverse biological processes, including smooth muscle contraction, energy homeostasis, and nociception.1It is an agonist of neuromedin-U receptor 1 (NMUR1; EC50= 0.17 nM for the human receptor in a calcium mobilization assay using HEK293 cells) and NMUR2 (EC50= ~1.4-2 nM for arachidonic acid release in CHO cells expressing the human receptor).2,3NMU-23 (1 μM) induces contractions in isolated rat colon smooth muscle strips.4It decreases body weight and food intake and increases core body temperature in mice when administered at a dose of 36 μg/animal.5Intrathecal administration of NMU-23 decreases the mechanical pain threshold in the von Frey test in rats.6 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBr. J. Pharmacol.158(1)87-103(2009) 2.Szekeres, P.G., Muir, A.I., Spinage, L.D., et al.Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3J. Biol. Chem.275(27)20247-20250(2000) 3.Hosoya, M., Moriya, T., Kawamata, Y., et al.Identification and functional characterization of a novel subtype of neuromedin U receptorJ. Biol. Chem.275(38)29528-29532(2000) 4.Brighton, P.J., Wise, A., Dass, N.B., et al.Paradoxical behavior of neuromedin U in isolated smooth muscle cells and intact tissueJ. Pharmacol. Exp. Ther.325(1)154-164(2008) 5.Peier, A., Kosinski, J., Cox-York, K., et al.The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2)Endocrinology150(7)3101-3109(2009) 6.Yu, X.H., Cao, C.Q., Mennicken, F., et al.Pro-nociceptive effects of neuromedin U in ratNeuroscience120(2)467-474(2003)

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)